insights_auto
ALNOV の下落理由: 3.30%?
さらに詳しくchevron_right
ALNOV:EPA
Novacyt SA
€0.43
arrow_downward
-3.30%(-0.014) 1 日
11月20日, 17:35:10 GMT+1 · EUR
search
すべての記号
| 記号 | 価格 | 変化 | 変化率 |
|---|
insights_autoALNOV の上位の分析情報を生成しています...
始値
€0.43
高値
€0.44
安値
€0.42
時価総額
2877.42万
平均出来高
12.80万
取引量
6.41万
52 週高値
€1.04
52 週安値
€0.29
EPS
-€0.37
発行済株式数
7258.81万
従業員数
228
始値
€0.43
高値
€0.44
安値
€0.42
時価総額
2877.42万
平均出来高
12.80万
取引量
6.41万
52 週高値
€1.04
52 週安値
€0.29
EPS
-€0.37
発行済株式数
7258.81万
従業員数
228
ニュース記事
情報源: ウェブソース、ニュース パートナー
プロフィール
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Novacyt SA について